Pleural mesothelioma is an aggressive disease that is enriched for inactivating alterations in tumor suppressor genes. Systemic therapeutic strategies for pleural mesothelioma generally involve ...

Preclinical studies indicate that cavity-resident macrophages in the peritoneal and pleural spaces contribute to immunosuppression and cancer progression. While these macrophages typically accumulate ...

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments. Lung cancer and pleural mesothelioma ...

Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in ...

Patients with malignant pleural mesothelioma are diagnosed at advanced stages and have limited treatment options. Patients with coexpression of ERCC1 and RPM1 in tumor tissues exhibited significantly ...

A new research paper titled "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable ...

A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination ...

To investigate their recruitment, Gata6-iCreER mice were crossed with Cd45-Dre and R26-tdT mice, enabling specific lineage tracing of cavity macrophages. Flow cytometry and immunofluorescence ...